EUVIMEDEUVIMED entdecken
Open Access

Central Nervous System Sarcoidosis: A National-Based registry study.

Yazan Al-Zamer, Sami Al-Horani, Marah Akhdar, Ghaydah Majali, Hamza Alzghoul, Moustafa Younis, Pouya Ameli, Bashar Alzghoul

Sarcoidosis vasculitis and diffuse lung diseases · 24.09.2024 · 41 (3) · e2024040-e2024040

DOI: 10.36141/svdld.v41i3.15103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sarcoidosis vasculitis and diffuse lung diseases, erschienen am 24.09.2024. Verfasst von Yazan Al-Zamer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jordan University of Science and Technology. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIM: Sarcoidosis of the central nervous system (CNS) often presents deleterious effects on affected patients. Data and available literature discussing the diagnosis and treatment of this condition are scarce and inconsistent. In this study, we aim to shed light on demographics, management, diagnostics, and clinical complications of CNS sarcoidosis patients within the United States (US) based on a nation-wide registry questionnaire. METHODS: Our retrospective study was conducted based on a national registry investigating 3,835 respondents to the Foundation for Sarcoidosis Research Sarcoidosis Advanced Registry for Cures Questionnaire (FSR-SARC). This national registry data was collected during the period of June 2014 to August 2019. We performed propensity score matching, summary, univariate, and multivariate analyses to establish a comparison between the presence and absence of central nervous system sarcoidosis. RESULTS: We identified a total of 420/3634 (11.55%) patients having CNS sarcoidosis; 296 (70.5%) were females, 307 (73.1%) were Caucasian and 81 (19.3%) were African American. The mean (±SD) age at diagnosis of CNS sarcoidosis was 43.3 (±12) years old. Multiorgan involvement (≥3 organs) was present in 318/420 (75.7%) patients. Brain magnetic resonance imaging was the most common ancillary diagnostic modality used and reported to be abnormal 251/328 (76.5%). Corticosteroids were the most used treatment by CNS sarcoidosis patients 206/420 (49.0%) followed by cytotoxic agents 180/420 (42.9%). CONCLUSIONS: CNS sarcoidosis prevalence in our cohort was similar to what has been described previously. The most prevalent imaging modality used was cranial MRI. Corticosteroids were the most used medications. Lastly, CNS sarcoidosis showed a propensity to cause several clinical complications such as chronic pain syndrome and disability.

Schlagwörter

central nervous system sarcoidosissarcoidosisprevalencedemographicscorticosteroid therapycytotoxic drugsbrain MRImultisystem involvementchronic pain syndromesdisability

Autor:innen und Institutionen

  • Jordan University of Science and Technology.
  • University of Central Florida College of Medicine.
  • Division of Pulmonary, Critical Care and Sleep Medicine; University of Florida; Gainesville, FL.
  • Division of Neurocritical Care, Departments of Neurology and Neurosurgery, University of Florida, Gainesville.

Zitieren

APA

Al-Zamer, Y., Al-Horani, S., Akhdar, M., Majali, G., Alzghoul, H., Younis, M., Ameli, P., & Alzghoul, B. (2024). Central Nervous System Sarcoidosis: A National-Based registry study. Sarcoidosis vasculitis and diffuse lung diseases, 41(3), e2024040-e2024040. https://doi.org/10.36141/svdld.v41i3.15103

Vancouver

Al-Zamer Y, Al-Horani S, Akhdar M, Majali G, Alzghoul H, Younis M, et al. Central Nervous System Sarcoidosis: A National-Based registry study. Sarcoidosis vasculitis and diffuse lung diseases. 2024;41(3):e2024040-e2024040. doi:10.36141/svdld.v41i3.15103

BibTeX
@article{AlZamer2024,
  author = {Al-Zamer, Yazan and Al-Horani, Sami and Akhdar, Marah and Majali, Ghaydah and Alzghoul, Hamza and Younis, Moustafa and Ameli, Pouya and Alzghoul, Bashar},
  title = {Central Nervous System Sarcoidosis: A National-Based registry study},
  journal = {Sarcoidosis vasculitis and diffuse lung diseases},
  year = {2024},
  volume = {41},
  number = {3},
  pages = {e2024040--e2024040},
  doi = {10.36141/svdld.v41i3.15103}
}
Kostenlos starten →